HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 in Japan
HUYA Bioscience International Announces Orphan Drug Designation for HBI-8000 in Japan
HBI-8000 granted orphan drug designation for peripheral T-cell lymphoma in Japan
San Diego, CA, USA – December 22, 2015 –HUYA Bioscience International (HUYA), Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).